Uy Ear
Stock Analyst at Mizuho Securities
(4.23)
# 1,511
Out of 4,698 analysts
604
Total ratings
46.2%
Success rate
8.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Maintained: Buy | $65 | $46.88 | +38.65% | 62 | Sep 4, 2026 | |
| TECX Tectonic Therapeutic | Reiterated: Buy | $85 | $29.92 | +184.09% | 35 | Aug 27, 2026 | |
| SLGL Sol-Gel Technologies | Reiterated: Buy | $285 | $70.10 | +306.56% | 2 | Aug 20, 2026 | |
| RLMD Relmada Therapeutics | Reiterated: Buy | $19 | $4.37 | +334.78% | 38 | Aug 11, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | $40 | $9.12 | +338.60% | 29 | Aug 11, 2026 | |
| INAB IN8bio | Maintained: Buy | $4 | $1.16 | +244.83% | 17 | Aug 11, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $91 | $61.42 | +48.16% | 13 | Aug 7, 2026 | |
| ARQT Arcutis Biotherapeutics | Reiterated: Buy | $35 → $36 | $23.66 | +52.16% | 164 | Aug 6, 2026 | |
| EOLS Evolus | Reiterated: Buy | $15 | $9.05 | +65.75% | 51 | Aug 5, 2026 | |
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $35 → $36 | $27.86 | +29.22% | 40 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $68 | $44.86 | +51.58% | 27 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $31 | $22.99 | +34.84% | 64 | Jul 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $146 → $175 | $158.35 | +10.51% | 38 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.35 | n/a | 13 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.48 | n/a | 9 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $14 | $4.29 | n/a | 1 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $14 | $36.62 | n/a | 1 | Jul 10, 2019 |
Alkermes
Sep 4, 2026
Maintained: Buy
Price Target: $65
Current: $46.88
Upside: +38.65%
Tectonic Therapeutic
Aug 27, 2026
Reiterated: Buy
Price Target: $85
Current: $29.92
Upside: +184.09%
Sol-Gel Technologies
Aug 20, 2026
Reiterated: Buy
Price Target: $285
Current: $70.10
Upside: +306.56%
Relmada Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $19
Current: $4.37
Upside: +334.78%
Cartesian Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $40
Current: $9.12
Upside: +338.60%
IN8bio
Aug 11, 2026
Maintained: Buy
Price Target: $4
Current: $1.16
Upside: +244.83%
MBX Biosciences
Aug 7, 2026
Reiterated: Buy
Price Target: $91
Current: $61.42
Upside: +48.16%
Arcutis Biotherapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $35 → $36
Current: $23.66
Upside: +52.16%
Evolus
Aug 5, 2026
Reiterated: Buy
Price Target: $15
Current: $9.05
Upside: +65.75%
ACADIA Pharmaceuticals
Aug 4, 2026
Reiterated: Buy
Price Target: $35 → $36
Current: $27.86
Upside: +29.22%
Jul 29, 2026
Reiterated: Buy
Price Target: $68
Current: $44.86
Upside: +51.58%
Jul 10, 2026
Maintained: Buy
Price Target: $31
Current: $22.99
Upside: +34.84%
Dec 12, 2025
Maintained: Hold
Price Target: $146 → $175
Current: $158.35
Upside: +10.51%
Aug 18, 2023
Rated: Hold
Price Target: n/a
Current: $1.35
Upside: n/a
Aug 11, 2023
Rated: Hold
Price Target: n/a
Current: $3.48
Upside: n/a
Jul 10, 2019
Initiated Coverage: Hold
Price Target: $14
Current: $4.29
Upside: n/a
Jul 10, 2019
Initiated Coverage: Hold
Price Target: $14
Current: $36.62
Upside: n/a